UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report

World journal of surgical oncology, 2023-03, Vol.21 (1), p.74-74, Article 74

2023

Volltextzugriff (PDF)

A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung

Modern pathology, 2020-04, Vol.33 (4), p.626-638

2020

Volltextzugriff (PDF)

Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion

Frontiers in oncology, 2022-07, Vol.12

2022

Volltextzugriff (PDF)

Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial

Journal of experimental & clinical cancer research, 2022-10, Vol.41 (1), p.1-300, Article 300

2022

Volltextzugriff (PDF)

Therapeutic targeting ERRγ suppresses metastasis via extracellular matrix remodeling in small cell lung cancer

EMBO molecular medicine, 2024-09, Vol.16 (9), p.2043-2059

2024

Volltextzugriff (PDF)

Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study

Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920968472-1758835920968472

2020

Volltextzugriff (PDF)

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

Journal of hematology and oncology, 2023-05, Vol.16 (1), p.50-50, Article 50

2023

Volltextzugriff (PDF)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-mutated NSCLC: A Prospective, Randomized, Exploratory Study

Cancer Research and Treatment, 2023, 55(3), , pp.841-850

2023

Volltextzugriff (PDF)

Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055)

Frontiers in oncology, 2020-08, Vol.10, p.1216-1216

2020

Volltextzugriff (PDF)

Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with high‐dose cisplatin

Cancer communications (London, England), 2023-02, Vol.43 (2), p.246-256

2023

Volltextzugriff (PDF)

Schizandrin A enhances the efficacy of gefitinib by suppressing IKKβ/NF-κB signaling in non-small cell lung cancer

European journal of pharmacology, 2019-07, Vol.855, p.10-19

2019

Volltextzugriff (PDF)

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study

Cancer communications (London, England), 2024-04, Vol.44 (4), p.455-468

2024

Volltextzugriff (PDF)

The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study

Frontiers in medicine, 2022-10, Vol.9, p.918468-918468

2022

Volltextzugriff (PDF)

Human induced-T-to-natural killer cells have potent anti-tumour activities

Biomarker research, 2022-03, Vol.10 (1), p.13-13, Article 13

2022

Volltextzugriff (PDF)

Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer

Cancer research (Chicago, Ill.), 2023-07, Vol.83 (13), p.2187-2207

2023

Volltextzugriff (PDF)

Cytotoxic pyridine alkaloids from a marine-derived fungus Arthrinium arundinis exhibiting apoptosis-inducing activities against small cell lung cancer

Phytochemistry (Oxford), 2023-09, Vol.213, p.113765-113765, Article 113765

2023

Volltextzugriff (PDF)

Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer

Cancer letters, 2023-06, Vol.564, p.216205-216205, Article 216205

2023

Volltextzugriff (PDF)

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial

The lancet respiratory medicine, 2020-01, Vol.8 (1), p.45-53

2020

Volltextzugriff (PDF)

Comparison of aprepitant versus desloratadine for EGFR‐TKI‐induced pruritus: A randomized phase 2 clinical trial

Cancer, 2022-11, Vol.128 (22), p.3969-3976

2022

Volltextzugriff (PDF)

Prognostic significance of platelet-to-lymphocyte ratio in patients with nasopharyngeal carcinoma: a meta-analysis

Future oncology (London, England), 2020-02, Vol.16 (5), p.117-127

2020

Volltextzugriff (PDF)

A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8008-8008

2024

Volltextzugriff (PDF)

Gefitinib plus chemotherapy versus gefitinib alone in untreated patients with EGFR -mutated non–small cell lung cancer and brain metastases (GAP Brain): An open-label, randomized, multicenter, phase 3 study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9095-9095

2022

Volltextzugriff (PDF)

Overexpressed transient receptor potential vanilloid 1 (TRPV1) in lung adenocarcinoma harbours a new opportunity for therapeutic targeting

Cancer gene therapy, 2022-10, Vol.29 (10), p.1405-1417

2022

Volltextzugriff (PDF)

Retraction Note: Overexpressed transient receptor potential vanilloid 1 (TRPV1) in lung adenocarcinoma harbours a new opportunity for therapeutic targeting

Cancer gene therapy, 2023-11, Vol.30 (11), p.1583-1583

2023

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(54)
Berichte
(1)

Sprache

Englisch
(55)

Erscheinungsjahr

n.n

Thema

Science & Technology
(43)
Life Sciences & Biomedicine
(39)
Oncology
(25)
Humans
(24)
Lung Neoplasms - Drug Therapy
(13)
Lung Cancer
(12)
Metastasis
(12)
Lung Neoplasms - Genetics
(10)
Patients
(10)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(9)
Chemotherapy
(9)
Female
(9)
Mutation
(8)
Cancer
(7)
Immunotherapy
(7)
Adult
(6)
Cancer Therapies
(6)
Carcinoma, Non-Small-Cell Lung - Genetics
(6)
Clinical Trials
(6)
General & Internal Medicine
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report

A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung

Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion

Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial

Therapeutic targeting ERRγ suppresses metastasis via extracellular matrix remodeling in small cell lung cancer

Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-mutated NSCLC: A Prospective, Randomized, Exploratory Study

Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055)

Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with high‐dose cisplatin

Schizandrin A enhances the efficacy of gefitinib by suppressing IKKβ/NF-κB signaling in non-small cell lung cancer

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study

The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study

Human induced-T-to-natural killer cells have potent anti-tumour activities

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer

Cytotoxic pyridine alkaloids from a marine-derived fungus Arthrinium arundinis exhibiting apoptosis-inducing activities against small cell lung cancer

Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial

Comparison of aprepitant versus desloratadine for EGFR‐TKI‐induced pruritus: A randomized phase 2 clinical trial

Prognostic significance of platelet-to-lymphocyte ratio in patients with nasopharyngeal carcinoma: a meta-analysis

A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091)

Gefitinib plus chemotherapy versus gefitinib alone in untreated patients with EGFR -mutated non–small cell lung cancer and brain metastases (GAP Brain): An open-label, randomized, multicenter, phase 3 study

Overexpressed transient receptor potential vanilloid 1 (TRPV1) in lung adenocarcinoma harbours a new opportunity for therapeutic targeting

Retraction Note: Overexpressed transient receptor potential vanilloid 1 (TRPV1) in lung adenocarcinoma harbours a new opportunity for therapeutic targeting

Suchergebnisse filtern